Unibest 优贝德
登录 / 注册
API 已商业化GMP/DMF内分泌 / 代谢

Orforglipron奥福格列酮龙

2 型糖尿病与肥胖症的口服治疗

CAS 号
2212020-52-3
适应症大类
代谢 / 内分泌
专利到期
专利状态待评估
治疗领域
内分泌 / 代谢
标示纯度
99%+
注册就绪度
GMP/DMF
商业化层级
API 已商业化
关联中间体
配套 23 项关键中间体
口服小分子 GLP-1非肽类产能优势
按 CAS 号询价全部中间体 →

该品种的关键中间体

排序：已上架可直发询价的在前；平台内被多个品种共用的通用片段靠前
中间体CAS平台共用操作
(2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-1-carboxylate2212021-56-0—
(4-Fluoro-3,5-dimethylphenyl)hydrazine hydrochloride2212021-40-2—
(E)-3-(2-(methyl(phenyl)carbamoyl)-1H-indol-5-yl)acrylic acid3047292-97-4—
(R,E)-N-methyl-5-(3-oxo-3-(2-oxo-4-phenyloxazolidin-3-yl)prop-1-en-1-yl)-N-phenyl-1H-indole-2-carboxamide3047293-00-2—
(R)-4-Benzyl-2-oxazolidinone102029-44-7—
(S)-3-Aminobutanenitrile Hydrochloride1073666-54-2—
(S)-5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-N-methyl-N-phenyl-1H-indole-2-carboxamide2212021-79-7—
1-(4-fluoro-1-methyl-1H-indazole-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-yl)-1,3-dihydro-2H-imidazole-2-one hydrochloride3036782-75-6—
1-(cyanomethyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-N-methyl-N-phenylindole-2-carboxamide2212021-80-0—
1,3,2-Dioxathiolane, 4-Methyl-, 2,2-dioxide, (4R)-1006381-03-8—
2H-Imidazol-2-one, 1-[(4S)-2-(4-fluoro-3,5- dimethylpheny1)-4,5,6,7-2H-Imidazol-2-one, 1-[(4S)-2- (4-fluoro-3,5-dimethylpheny1)-4,5,6,7-1H- indazol-5- yl)- 1,3-dihydro-2212022-56-3—
3-(3-(4-fluoro-1-methyl-1H-indazole-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester3036782-74-5—
5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid2212021-83-3—
5-Bromo-2-fluoro-m-xylene99725-44-7—
5-Bromo-4-fluoro-1-methyl-1H-indazole1784678-61-0—
5-bromo-N-methyl-N-phenyl-1H-indole-2-carboxamide2860499-50-7—
5-Bromoindole-2-carboxylic acid7254-19-5—
5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(2,3-dihydro-2-oxo-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4S)-2212021-61-7—
H-Indole-2-carboxamide, 1-[(1S,2S)-1-cyano-2-methylcyclopropyl]-N-methyl-N-phenyl-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-2212021-81-1—
N-Boc-L-Alaninol79069-13-9—
tert-buty1 (S)-3-amino-2-(4- fluoro-3,5- dimethylpheny1)-4- methyl-2,4,6,7-tetrahydro-5H-pyrazoloB ,3-c ]pyridine-5-carboxylate2212021-59-3—
tert-butyl 2-(4-fluoro-3,5-dimethylphenyl)-3-(2-oxo-1H-imidazol-3-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate2212022-03-0—
tert-butyl 3-amino-2-(4-fluoro-3,5-dimethylphenyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate2212021-41-3—

发布逻辑 · 为什么值得上线

口服小分子 GLP-1 受体激动剂，无需注射且可化学合成放大，相较多肽更易放量上市，是最受关注的下一代减重分子。

需求侧

内分泌 / 代谢 · 已上市、可即采即用

合规侧

GMP/DMF 就绪，可支撑目标市场的注册申报与审计

供应侧

配套 23 项关键中间体，量产与降本可控

产品说明 · Product Description

Orforglipron is a small molecule (non-peptide) GLP-1 receptor agonist that helps control blood glucose and reduce appetite by mimicking the action of natural GLP-1. It stimulates insulin secretion, inhibits glucagon release, and slows down gastric emptying, primarily used for blood glucose management and long-term weight control (obesity/overweight) in type 2 diabetes.

供应来源：优贝德 Unibest · Orforglipron，由优贝德统一对接、审核与交付。治疗领域、适应症与发布逻辑为基于公开药物知识的定性整理；具体注册可用性与质量指标以 DMF / GMP 文件及订单确认的技术协议为准。